Tags

Type your tag names separated by a space and hit enter

C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats.
Diabetes Metab Res Rev 2007; 23(1):63-70DM

Abstract

BACKGROUND

The spontaneously diabetic BB/Wor-rat is a close model of human type 1 diabetes and develops diabetic polyneuropathy (DPN) similar to that seen in type 1 patients. Here we examine the therapeutic effects of C-peptide, delivered as continuous infusion or once daily subcutaneous injections on established DPN.

METHODS

Diabetic rats were treated from four to seven months duration of diabetes with full continuous replacement dose of rat C-peptide via (a) osmopumps (OS), (b) full replacement dose (HSC) or (c) one-third of full replacement dose (LSC) by once daily injections.

RESULTS

Diabetic rats treated with OS showed improvements in motor nerve conduction velocity (p < 0.001), sural nerve myelinated fibre number (p < 0.005), size (p < 0.05), axonal area (p < 0.001), regeneration (p < 0.001) and overall neuropathy score (p < 0.001). The progressive decline in sensory nerve conduction velocity was fully prevented. The frequencies of Wallerian degeneration were decreased (p < 0.005). HSC-treated rats showed prevention of further progression of DPN (p < 0.001), whereas LSC-treated rats showed a milder progression of DPN (p < 0.001) compared to untreated rats as assessed by neuropathy score.

CONCLUSION

We conclude that (1) C-peptide is effective in the treatment of established DPN, (2) its effect is dose-dependent and (3) replacement by continuous infusion is the most effective administration of C-peptide.

Authors+Show Affiliations

Department of Pathology, Wayne State University, School of Medicine, Detroit, MI 48201, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16845685

Citation

Zhang, Weixian, et al. "C-peptide Improves Neuropathy in Type 1 Diabetic BB/Wor-rats." Diabetes/metabolism Research and Reviews, vol. 23, no. 1, 2007, pp. 63-70.
Zhang W, Kamiya H, Ekberg K, et al. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes Metab Res Rev. 2007;23(1):63-70.
Zhang, W., Kamiya, H., Ekberg, K., Wahren, J., & Sima, A. A. (2007). C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes/metabolism Research and Reviews, 23(1), pp. 63-70.
Zhang W, et al. C-peptide Improves Neuropathy in Type 1 Diabetic BB/Wor-rats. Diabetes Metab Res Rev. 2007;23(1):63-70. PubMed PMID: 16845685.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. AU - Zhang,Weixian, AU - Kamiya,Hideki, AU - Ekberg,Karin, AU - Wahren,John, AU - Sima,Anders A F, PY - 2006/7/18/pubmed PY - 2007/2/27/medline PY - 2006/7/18/entrez SP - 63 EP - 70 JF - Diabetes/metabolism research and reviews JO - Diabetes Metab. Res. Rev. VL - 23 IS - 1 N2 - BACKGROUND: The spontaneously diabetic BB/Wor-rat is a close model of human type 1 diabetes and develops diabetic polyneuropathy (DPN) similar to that seen in type 1 patients. Here we examine the therapeutic effects of C-peptide, delivered as continuous infusion or once daily subcutaneous injections on established DPN. METHODS: Diabetic rats were treated from four to seven months duration of diabetes with full continuous replacement dose of rat C-peptide via (a) osmopumps (OS), (b) full replacement dose (HSC) or (c) one-third of full replacement dose (LSC) by once daily injections. RESULTS: Diabetic rats treated with OS showed improvements in motor nerve conduction velocity (p < 0.001), sural nerve myelinated fibre number (p < 0.005), size (p < 0.05), axonal area (p < 0.001), regeneration (p < 0.001) and overall neuropathy score (p < 0.001). The progressive decline in sensory nerve conduction velocity was fully prevented. The frequencies of Wallerian degeneration were decreased (p < 0.005). HSC-treated rats showed prevention of further progression of DPN (p < 0.001), whereas LSC-treated rats showed a milder progression of DPN (p < 0.001) compared to untreated rats as assessed by neuropathy score. CONCLUSION: We conclude that (1) C-peptide is effective in the treatment of established DPN, (2) its effect is dose-dependent and (3) replacement by continuous infusion is the most effective administration of C-peptide. SN - 1520-7552 UR - https://www.unboundmedicine.com/medline/citation/16845685/C_peptide_improves_neuropathy_in_type_1_diabetic_BB/Wor_rats_ L2 - https://doi.org/10.1002/dmrr.672 DB - PRIME DP - Unbound Medicine ER -